新型肽基放射性示踪剂用于检测PD-L1表达并指导癌症免疫治疗的研究
本研究制备了靶向PD-L1的肽基示踪剂[68Ga]NOTA-IMB与[18F]AlF-NOTA-IMB,在细胞与荷瘤小鼠中验证其亲和力与特异性,并通过PET显像监测阿替利珠单抗治疗后PD-L1表达的动态变化,显示两种示踪剂可无创定量检测PD-L1表达并监测免疫治疗疗效。
要点
- 两种示踪剂放射化学产率分别为>95%与>60%,放射化学纯度分别为>95%与>98%(n=5)。
- 在人源与鼠源PD-L1上Kd分别为1.00±0.16/1.09±0.21 nM与1.56±0.58/1.21±0.39 nM(n=3)。
- 阿替利珠单抗治疗五次后,两种示踪剂肿瘤摄取分别由3.30±0.29降至1.58±0.29%ID/mL与由3.27±0.63降至0.89±0.18%ID/mL。
核心结论
- [68Ga]NOTA-IMB与[18F]AlF-NOTA-IMB成功制备,可无创、定量地PET显像PD-L1表达。
- 两种示踪剂能灵敏检测免疫治疗引起的PD-L1表达动态变化。
- 作者认为该肽基示踪剂可用于准确检测不同肿瘤的PD-L1表达并监测免疫治疗疗效。
研究设计与样本
- 研究制备NOTA-IMB并通过NOTA-NHS与PD-L1靶向肽IMB连接,进一步用68Ga或18F-AlF进行放射性标记。
- 体外结合实验确认[68Ga]/[18F]AlF-NOTA-IMB检测PD-L1表达的能力。
- 在不同荷瘤小鼠中进行[68Ga]NOTA-IMB与[18F]AlF-NOTA-IMB的体内PET显像,并监测免疫治疗诱导的PD-L1表达水平动态变化。
- 采用放射自显影、蛋白质印迹、免疫荧光染色与生物分布分析进一步评估示踪剂特异性与PD-L1抗体免疫治疗疗效。
主要发现
- [68Ga]NOTA-IMB与[18F]AlF-NOTA-IMB均成功制备,放射化学产率分别>95%与>60%(n=5),放射化学纯度分别>95%与>98%(n=5)。
- 两种示踪剂对人源与鼠源PD-L1均显示高亲和力,Kd分别为1.00±0.16/1.09±0.21 nM(A375-hPD-L1,n=3)与1.56±0.58/1.21±0.39 nM(MC38,n=3)。
- 体外细胞摄取实验显示两种示踪剂可特异性结合PD-L1阳性细胞A375-hPD-L1与MC38,120 min时摄取分别为5.45±0.33/3.65±0.15%AD与5.87±0.27/2.78±0.08%AD(n=3)。
- 体内PET显像与生物分布分析显示[68Ga]NOTA-IMB与[18F]AlF-NOTA-IMB在A375-hPD-L1与MC38肿瘤中高蓄积,而在A375肿瘤中摄取低。
- 阿替利珠单抗治疗五次后,MC38荷瘤小鼠[68Ga]NOTA-IMB肿瘤摄取由3.30±0.29%ID/mL降至1.58±0.29%ID/mL(n=3,P=0.026),[18F]AlF-NOTA-IMB由3.27±0.63%ID/mL降至0.89±0.18%ID/mL(n=3,P=0.0004);PBS治疗前后肿瘤摄取未见显著差异。
关键数值与推荐
- [68Ga]NOTA-IMB放射化学产率>95%、放射化学纯度>95%(n=5);[18F]AlF-NOTA-IMB放射化学产率>60%、放射化学纯度>98%(n=5)。
- [68Ga]NOTA-IMB与[18F]AlF-NOTA-IMB对A375-hPD-L1的Kd分别为1.00±0.16 nM与1.09±0.21 nM(n=3)。
- [68Ga]NOTA-IMB与[18F]AlF-NOTA-IMB对MC38的Kd分别为1.56±0.58 nM与1.21±0.39 nM(n=3)。
- 阿替利珠单抗治疗五次后[68Ga]NOTA-IMB肿瘤摄取由3.30±0.29%ID/mL降至1.58±0.29%ID/mL(n=3,P=0.026)。
- 阿替利珠单抗治疗五次后[18F]AlF-NOTA-IMB肿瘤摄取由3.27±0.63%ID/mL降至0.89±0.18%ID/mL(n=3,P=0.0004)。
临床怎么用
- 作者认为[68Ga]NOTA-IMB与[18F]AlF-NOTA-IMB可用于准确检测不同肿瘤的PD-L1表达并监测免疫治疗疗效。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Due to tumor heterogeneity, immunohistochemistry (IHC) showed poor accuracy in detecting the expression of programmed cell death ligand-1 (PD-L1) in patients. Positron emission tomography (PET) imaging is considered as a non-invasive technique to detect PD-L1 expression at the molecular level visually, real-timely and quantitatively. This study aimed to develop novel peptide-based radiotracers [68Ga]/[18F]AlF-NOTA-IMB for accurately detecting the PD-L1 expression and guiding the cancer immunotherapy. METHODS: NOTA-IMB was prepared by connecting 2,2'-(7-(2-((2,5-dioxopyrrolidin-1-yl)oxy)- 2-oxoethyl)-1,4,7-triazonane-1,4-diyl) diacetic acid (NOTA-NHS) with PD-L1-targeted peptide IMB, and further radiolabeled with 68Ga or 18F-AlF. In vitro binding assay was conducted to confirm the ability of [68Ga]/[18F]AlF-NOTA-IMB to detect the expression of PD-L1. In vivo PET imaging of [68Ga]NOTA-IMB and [18F]AlF-NOTA-IMB in different tumor-bearing mice was performed, and dynamic changes of PD-L1 expression level induced by immunotherapy were monitored. Radioautography, western blotting, immunofluorescence staining and biodistribution analysis were carried out to further evaluate the specificity of radiotracers and efficacy of PD-L1 antibody immunotherapy. RESULTS: [68Ga]NOTA-IMB and [18F]AlF-NOTA-IMB were both successfully prepared with high radiochemical yield (> 95% and > 60%, n = 5) and radiochemical purity (> 95% and > 98%, n = 5). Both tracers showed high affinity to human and murine PD-L1 with the dissociation constant (Kd) of 1.00 ± 0.16/1.09 ± 0.21 nM (A375-hPD-L1, n = 3) and 1.56 ± 0.58/1.21 ± 0.39 nM (MC38, n = 3), respectively. In vitro cell uptake assay revealed that both tracers can specifically bind to PD-L1 positive cancer cells A375-hPD-L1 and MC38 (5.45 ± 0.33/3.65 ± 0.15%AD and 5.87 ± 0.27/2.78 ± 0.08%AD at 120 min, n = 3). In vivo PET imaging and biodistribution analysis showed that the tracer [68Ga]NOTA-IMB and [18F]AlF-NOTA-IMB had high accumulation in A375-hPD-L1 and MC38 tumors, but low uptake in A375 tumor. Treatment of Atezolizumab induced dynamic changes of PD-L1 expression in MC38 tumor-bearing mice, and the tumor uptake of [68Ga]NOTA-IMB decreased from 3.30 ± 0.29%ID/mL to 1.58 ± 0.29%ID/mL (n = 3, P = 0.026) after five treatments. Similarly, the tumor uptake of [18F]AlF-NOTA-IMB decreased from 3.27 ± 0.63%ID/mL to 0.89 ± 0.18%ID/mL (n = 3, P = 0.0004) after five treatments. However, no significant difference was observed in the tumor uptake before and after PBS treatment. Biodistribution, radioautography, western blotting and immunofluorescence staining analysis further demonstrated that the expression level of PD-L1 in tumor-bearing mice treated with Atezolizumab significantly reduced about 3 times and correlated well with the PET imaging results. CONCLUSION: [68Ga]NOTA-IMB and [18F]AlF-NOTA-IMB were successfully prepared for PET imaging the PD-L1 expression noninvasively and quantitatively. Dynamic changes of PD-L1 expression caused by immunotherapy can be sensitively detected by both tracers. Hence, the peptide-based radiotracers [68Ga]NOTA-IMB and [18F]AlF-NOTA-IMB can be applied for accurately detecting the PD-L1 expression in different tumors and monitoring the efficacy of immunotherapy.
引用
- Zhu S, Liang B, Zhou Y, et al. Development of novel peptide-based radiotracers for detecting PD-L1 expression and guiding cancer immunotherapy. Eur J Nucl Med Mol Imaging. 2023. PMID: 37878029. doi:10.1007/s00259-023-06480-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。